CIK 0000818686 · Large accelerated filer
TEVA PHARMACEUTICAL INDUSTRIES LTD
Sign in to watch- Ticker
- TEVA
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Israel
- Entity type
- operating
- Phone
- 972 (3) 914-8213
- Business address
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED, 124 DVORA HANEVI'A ST., TEL AVIV, Israel
- Former names
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $33,923,078
- in 11 filings, $11.2M under 10b5-1 plans
Net −$33,923,078. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-04 | Bergwerk Dov Interim Cheif Legal Officer | Option exercise | +17,505 | $34.70 | $607K | 29,448 |
| 2026-11-04 | Bergwerk Dov Interim Cheif Legal Officer | Sale | −17,505 | $41.72 | $730K | 11,943 |
| 2026-11-04 | Bergwerk Dov Interim Cheif Legal Officer | Option exercise | +8,755 | $28.98 | $254K | 20,698 |
| 2026-11-04 | Bergwerk Dov Interim Cheif Legal Officer | Sale | −8,755 | $41.72 | $365K | 11,943 |
| 2026-11-04 | Bergwerk Dov Interim Cheif Legal Officer | Option exercise · Stock Options (right to buy) | −17,505 | 0 | ||
| 2026-11-04 | Bergwerk Dov Interim Cheif Legal Officer | Option exercise · Stock Options (right to buy) | −8,755 | 0 | ||
| 2026-09-18 | Savage Brian Interim Chief Legal Officer | Option exercise | +4,503 | $34.70 | $156K | 15,842 |
| 2026-09-18 | Savage Brian Interim Chief Legal Officer | Sale | −4,503 | $38.69 | $174K | 11,339 |
| 2026-09-18 | Savage Brian Interim Chief Legal Officer | Sale | −2,525 | $39.15 | $99K | 8,814 |
| 2026-09-18 | Savage Brian Interim Chief Legal Officer | Sale | −314 | $38.70 | $12K | 8,500 |
| 2026-09-18 | Savage Brian Interim Chief Legal Officer | Option exercise · Stock Options (right to buy) | −4,503 | $34.70 | $156K | 0 |
| 2026-09-18 | MIGNONE ROBERTO Director | Sale | −367,600 | $39.06 | $14.4M | 0 |
| 2026-08-21 | Weiss Amir Chief Accounting Officer | Sale | −6,945 | $37.61 | $261K | 13,071 |
| 2026-08-21 | Weiss Amir Chief Accounting Officer | Option exercise | +2,500 | $19.61 | $49K | 15,571 |
| 2026-08-21 | Weiss Amir Chief Accounting Officer | Sale | −2,500 | $37.63 | $94K | 13,071 |
| 2026-08-21 | Weiss Amir Chief Accounting Officer | Option exercise · Stock Options (right to buy) | −2,500 | $19.16 | $48K | 7,502 |
| 2026-08-21 | Satchi-Fainaro Ronit Director | Sale | −415 | $37.25 | $15K | 111,986 |
| 2026-08-17 | Lippman Evan EVP, Business Development | Sale 10b5-1 | −18,600 | $36.57 | $680K | 25,591 |
| 2026-08-05 | Zaks Tal Zvi Director | Sale | −17 | $34.87 | $593 | 73,247 |
| 2026-08-03 | Jover Placid See "Remarks" | Option exercise 10b5-1 | +12,827 | 19,601 |
Page 2 of 64 · 1,279 trades